Related Experiment Video
Updated: Sep 28, 2025
07:59
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
2.7K
Endocan-microvascular Density in Primary Ovarian Carcinoma
Farahlina Baba1,2, Aidy Irman Yajid1,2, Siti Norasikin Mohd Nafi1,2
1Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Malaysia.
Asian Pacific Journal of Cancer Prevention : APJCP
|March 29, 2022
Summary
Endocan-microvascular density (MVD) is associated with key clinicopathological factors in epithelial ovarian cancer. High endocan-MVD levels correlate with older age, smaller tumors, advanced stage, and recurrence, suggesting its potential as a prognostic marker.
Area of Science:
- Oncology
- Pathology
- Biomarker Research
Background:
- Epithelial ovarian cancer is a leading cause of cancer death in women.
- Angiogenesis, evaluated by microvascular density (MVD), drives ovarian cancer progression.
- Endocan is a potential biomarker for assessing angiogenesis in ovarian cancer.
Purpose of the Study:
- To investigate the association between endocan-MVD and clinicopathological factors in primary epithelial ovarian cancer.
- To determine if endocan-MVD can serve as a prognostic indicator for ovarian cancer.
Main Methods:
- Retrospective analysis of 89 epithelial ovarian cancer cases (2008-2018).
- Immunohistochemistry used to quantify endocan and MVD.
- Statistical analysis (Pearson chi-square, Fischer's exact test) to assess associations.
Main Results:
- All epithelial ovarian carcinomas were positive for endocan.
- High endocan-MVD showed significant associations with older age, smaller tumor size, type II tumors, high tumor grade, advanced FIGO stage, and tumor recurrence.
- No significant association was found with race, CA-125, diabetes, endometriosis, lymph node involvement, metastasis, or family history.
Conclusions:
- Endocan-MVD is significantly associated with several adverse prognostic factors in epithelial ovarian cancer.
- Endocan-MVD shows promise as a reliable biomarker for predicting prognosis in ovarian cancer patients.
